| Literature DB >> 25342166 |
Dane Wildner1, Deike Strobel1, Peter C Konturek2, Rüdiger S Görtz1, Roland S Croner3, Markus F Neurath1, Steffen Zopf1.
Abstract
BACKGROUND: Acoustic radiation force impulse (ARFI) elastography is a reliable diagnostic device for quantitative non-invasive assessment of liver fibrosis in patients with chronic liver disease. The aim of our prospective study was to evaluate the impact of ARFI in patients after orthotopic liver transplantation (OLT). Therefore, we compared ARFI shear wave velocities with clinical features, non-invasive markers, and the histology of patients following OLT.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25342166 PMCID: PMC4218901 DOI: 10.12659/MSM.891126
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Figure 1Ultrasound examination in a patient after orthotopic liver transplantation [Fibrosis stage (Ludwig) F2] (A) B-mode US showing irregular hepatic veins, inhomogeneous parenchyma, and an irregular liver surface. (B) ARFI elastometry during real-time B-mode US. Placement of the quadratic cursor in the region-of-interest by an intercostal approach in the right liver lobe (Segment VII). ARFI shear-wave-velocities (Vs) are displayed in m/s and the depth of measurement in centimeters (cm).
Patient characteristics (laboratory standard value or value range in parentheses). Correlation of individual parameters with mean ARFI-velocity in the right liver lobe.
| Patient characteristics | r | p-value | |
|---|---|---|---|
| Total (n) | 58 (100%) | ||
| Male (n) | 37 (64%) | −0.10 | n.s. |
| Female (n) | 21 (36%) | 0.10 | n.s. |
| Age (years; mean, SD) | 55±12 | −0.35 | p<0.05 |
| BMI (kg/m2 mean, SD) | 25.9±4.1 | −0.40 | p<0.05 |
| Years since OLT (mean, SD) | 11.6±23.2 | −0.25 | n.s. |
| Hepatocellular carcinoma | 15 (26%) | ||
| Alcoholic liver disease | 13 (22%) | ||
| Drug-induced liver failure | 6 (10%) | ||
| Hepatitis C | 5 (9%) | ||
| Hepatitis B | 4 (7%) | ||
| Morbus Wilson | 3 (5%) | ||
| Primary sclerosing cholangitis | 3 (5%) | ||
| Others | 9 (16%) | ||
| None | 1 (2%) | ||
| CSA or TAC mono | 35 (60%) | ||
| EVE + Steroid | 1 (2%) | ||
| TAC or CSA + MMF | 12 (20%) | ||
| TAC or CSA + MMF + Steroid | 8 (14%) | ||
| EVE + MMF + Steroid | 1 (2%) | ||
| Total bilirubin (<1.1 mg/dl) | 1.15±1.6 | 0.45 | p<0.001 |
| AST (<50 U/l) | 48.9±60.6 | 0.52 | p<0.001 |
| ALT (<50 U/l) | 50.4±75.4 | 0.44 | p<0.001 |
| γ-GT (<60 U/l) | 146.6±234.9 | 0.33 | p<0.05 |
| AP (40–130 U/l) | 150.4±146 | 0.42 | p<0.05 |
| Albumin (35–55 mg/dl) | 41.5±8.2 | −0.30 | p<0.05 |
| Platelet count (140–400×103/μl) | 191.0±856 | 0.06 | n.s. |
| APRI-Score | 0.83±1.35 | 0.44 | p<0.001 |
Correlation coefficient (r);
BMI – Body Mass Index; OLT – orthotopic liver transplantation; CSA – cyclosporin A; TAC – Tacrolimus; EVE – Everolimus; MMF – Mycophenolate mofetil.
Figure 2Acoustic radiation force impulse imaging elastometry in patients following OLT. Box plots [median as thick line through each box which represents interquartile range within which 50% of values are located, first and third quartile, error bars mark minimum and maximum values (range), * outlier] showing the significantly increased ARFI-values in patients with (A) an advanced degree of fibrosis ≥F3 (Ludwig Score); (B) cholestasis and (C) active viral hepatitis.
ARFI shear-wave velocities (mean ± standard deviation): distribution of values dependent on the site of determination, cholestasis, presence of active viral hepatitis, and histological classification after LB.
| Total (n=58) | ARFI-velocity (m/s) | Intra-individual Standard Deviation | p-value |
|---|---|---|---|
| Segment III (n=58) | 2.00±0.93 | 0.31±0.19 | p<0.001 |
| Segment VII (n=58) | 1.39±0.63 | 0.16±0.11 | |
| Cholestasis No (n=51) | 1.33±0.59 | 0.15±0.09 | p<0.05 |
| Cholestasis Yes (n=7) | 1.83±0.84 | 0.23±0.19 | |
| Active viral hepatitis No (n=48) | 1.26±0.46 | 0.15±0.09 | p<0.001 |
| Active viral hepatitis Yes (n=10) | 2.03±0.94 | 0.22±0.15 | |
| Rejection No (n=13) | 2.04±0.92 | 0.25±0.17 | n.s. |
| Rejection Yes (n=9) | 1.60±0.49 | 0.17±0.07 | |
| Inflammation No (n=12) | 1.68±0.67 | 0.20±0.15 | n.s. |
| Inflammation Yes (n=10) | 2.08±0.90 | 0.23±0.14 | |
| Fibrosis stage 0–2 (n=17) | 1.57±0.57 | 0.17±0.07 | p<0.001 |
| Fibrosis stage ≥3 (n=5) | 2.85±0.66 | 0.38±0.20 |
ROC analysis for the diagnostic accuracy and cut-offs of ARFI velocities for evaluating the stage of liver fibrosis.
| Fibrosis stage | AUC | Standard error | p-value | 95% Confidence Interval | Cutoff value (m/s) | Sensitivity (%) | Specificity (%) | |
|---|---|---|---|---|---|---|---|---|
| Lower bound | Upper bound | |||||||
| ≥F1 | 0.741 | 0.124 | 0.108 | 0.499 | 0.984 | 1.48 | 65 | 80 |
| ≥F2 | 0.727 | 0.111 | 0.071 | 0.510 | 0.945 | 1.75 | 64 | 82 |
| ≥F3 | 0.929 | 0.056 | 0.004 | 0.819 | 1.000 | 2.02 | 100 | 88 |
| =F4 | 0.800 | 0.089 | 0.171 | 0.625 | 0.975 | 2.29 | 100 | 80 |
Figure 3Receiver operating characteristic curves for the determination of different stages of liver fibrosis by ARFI.